Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology

References

• Bodey GP, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy study. Eur J Clin Microbiol Infect Dis 1992; 11: 99–109
   PubMed Web of Science ®Google Scholar
• Groll A, Shah P, Menzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23–32
   PubMed Web of Science ®Google Scholar
• Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–615
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, Boogaerts M, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant to conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658–666
   PubMed Web of Science ®Google Scholar
• Moore BC, Sayers N, Mosquera J, Slaven J, Denning DW. Antifungal drug resistance in Aspergillus. J Infect 2000; 41: 203–220
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedures for antifungal susceptibility testing of filamentous fungi. J Cin Microbiol 1997; 35: 139–143
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998; 36: 198–202
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995; 39: 314–319
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tudela JL, Chryssanthou E, Petrikkou E, et al. Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Cin Microbiol 2003; 41: 5236–5237
   Web of Science ®Google Scholar
• Rex J, Pfaller M, Walsh T, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643–658
   PubMed Web of Science ®Google Scholar
• Denning DW, Radford SA, Oakley KL, et al. Correlation between in vitro susceptibility testing to itraconazole and in vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401–414
   PubMed Web of Science ®Google Scholar
• Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364–1368
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standard Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. M38-A. WaynePA. Clinical Laboratory Standard Institute, 2002.
   Google Scholar
• Gehrt A, Peter J, Pizzo P, Walsh T. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol 1995; 33: 1302–1307
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Meis J, Mouton J, Verweij PE. Analysis of growth characteristics of filamentous fungi in different nutrient media. J Clin Microbiol 2001; 39: 478–484
   PubMed Web of Science ®Google Scholar
• Gomez-Lopez A, Aberkane A, Petrikkou E, Mellado E, Rodriguez-Tudela JL. Analysis of the influence of tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. J Clin Microbiol 2005; 43: 1251–1255
   PubMed Web of Science ®Google Scholar
• Aberkane A, Cuenca-Estrella M, Gomez-Lopez A, et al. Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J Antimicrob Chemother 2002; 50: 719–722
   PubMed Web of Science ®Google Scholar
• Petrikkou E, Rodriguez-Tudela JL, Cuenca-Estrella M, et al. Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J Clin Microbiol 2001; 39: 1345–1347
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J Clin Microbiol 2003; 41: 403–409
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller M, Rinaldi MG, Polak A, Galgani NJ. Antifungal susceptibility testing. Clin Microbiol Rev 1993; 38: 367–381
   Google Scholar
• Espinel-Ingroff A. Utility of mould susceptibility testing. Curr Opin Infect Dis 2003; 16: 527–532
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3776–3781
   PubMed Web of Science ®Google Scholar
• Walsh T, Petraitis V, Petraitiene, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188: 305–319
   PubMed Web of Science ®Google Scholar
• Johnson EM, Oakley KL, Radford SA, et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000; 45: 85–93
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204–3208
   PubMed Web of Science ®Google Scholar
• Peterson L, Shanholtzer C. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev 1992; 5: 420–432
   PubMed Web of Science ®Google Scholar
• Subcommittee of Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. EUCAST discussion document. E.Dis.7.1.ESCMID.Taufkirchen, 2002.
   Google Scholar
• Pfaller M, Messer SA, Mills K, Bolmstrom A. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol 2000; 38: 3359–3361
   PubMed Web of Science ®Google Scholar
• Szekely A, Johnson E, Warnock D. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of moulds. J Clin Microbiol 1999; 37: 1480–1483
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Mouton J, Meis J, Bouman B, Verweij PE. Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2002; 40: 2876–2885
   PubMed Web of Science ®Google Scholar
• Jahn B, Stuben A, Bhakdi S. Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5- diphenyl-2H-tetrazolium bromide and alamar blue tests. J Clin Microbiol 1996; 34: 2039–2041
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Meis J, Mouton JW, Donnelly JP, Verweij PE. Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000; 38: 2949–2954
   PubMed Web of Science ®Google Scholar
• Martin-Mazuelos E, Peman J, Valverde A, et al. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003; 52: 365–370
   PubMed Web of Science ®Google Scholar
• Ramani R, Gangwar M, Chaturvedi V. Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-a-vis amphotericin B and itraconazole. Antimicrob Agents Chemother 2003; 47: 3627–3629
   PubMed Web of Science ®Google Scholar
• Balajee SA, Marr KA. Conidial viability assay for rapid susceptibility testing of Aspergillus species. J Clin Microbiol 2002; 40: 2741–2745
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C, Nagl M, Speth C, et al. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 2001; 45: 124–128
   PubMed Web of Science ®Google Scholar
• Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46: 556–557
   PubMed Web of Science ®Google Scholar
• Warris A, Weemaes C, Verweij PE. Multidrug resistance in Aspergillus fumigatus. N Engl J Med 2002; 347: 2173–2174
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single center experience. Br J Haematol 2005; 131: 201–207
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Lewis RE, Torres HA, et al. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005; 52: 15–20
   PubMed Web of Science ®Google Scholar
• Marr AK, Carter R, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Moosa MY, Alangaden GJ, Manavathu E, Chandrasekar PH. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis. J Antimicrob Chemother 2002; 49: 209–213
   PubMed Web of Science ®Google Scholar
• Warn PA, Morrissey G, Morrissey J, Denning DW. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913–919
   PubMed Web of Science ®Google Scholar
• Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 2005; 55: 31–37
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Persat F, Monier MF, et al. In vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J Antimicrob Chemother 1999; 44: 553–555
   PubMed Web of Science ®Google Scholar
• Verweij PE, Te Dorsthorst DT, Rijs AM, Vries-Hospers HG, Meis JF. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between and 1998. J Clin Microbiol ; 40 1945; 2002: 2648–2650
   Google Scholar
• Howard SJ, Moore BC, Denning DW. Azole resistance in Aspergillus niger. Advances against Aspergillosis, Athen 2006, Poster 071.
   Google Scholar
• Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B acquired resistance to itraconazole. Scand J Infect Dis 1997; 29: 509–512
   PubMed Web of Science ®Google Scholar
• Verweij PE, Mensink M, Donnely JP, Meis J, Denning D. In vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 1998; 42: 389–392
   PubMed Web of Science ®Google Scholar
• Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A Point mutation in the 14{alpha}-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2003; 47: 1120–1124
   PubMed Web of Science ®Google Scholar
• Osherov N, Kontoyiannis DP, Romans A, May GS. Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14{alpha}-demethylase gene, pdmA. J Antimicrob Chemother 2001; 48: 75–81
   PubMed Web of Science ®Google Scholar
• Mann PA, Parmegiani RM, Wei SQ, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14 -demethylase. Antimicrob Agents Chemother 2003; 47: 577–581
   PubMed Web of Science ®Google Scholar
• Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1504–1507
   PubMed Web of Science ®Google Scholar